Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial
10 déc. 2024 06h00 HE
|
Cardiff Oncology, Inc.
- Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control...
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
30 oct. 2024 16h30 HE
|
Cardiff Oncology, Inc.
- Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical activity and is well tolerated in second-line KRAS-mutant mCRC - - Post hoc analysis...
Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update
08 août 2024 16h05 HE
|
Cardiff Oncology, Inc.
- Initial readout from first-line RAS-mut. mCRC randomized CRDF-004 trial expected in 2H 2024 - - Published preclinical data underscores the ability of onvansertib to overcome resistance to PARP...
Cardiff Oncology to Present at Upcoming Investor Conferences in May
13 mai 2024 16h05 HE
|
Cardiff Oncology, Inc.
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
06 mars 2024 16h05 HE
|
Cardiff Oncology, Inc.
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference
26 févr. 2024 08h00 HE
|
Cardiff Oncology, Inc.
SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update
22 févr. 2024 08h00 HE
|
Cardiff Oncology, Inc.
- Management will hold a conference call on Thursday, February 29 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage...